SCHEMBL29909748

SCHEMBL29909748

CN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1)c1nc2nnc(F)n2c2cc(Oc3ccc(C(F)(F)F)cc3)ccc12

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 7/20 0.40
DHODH Q02127 1/20 0.33
KDM4E B2RXH2 2/20 0.32
LMNA P02545 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
EGFR P00533 2/20 0.32
CSF1R P07333 2/20 0.32
NPC1 O15118 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
LIPE Q05469 2/20 0.31
TNK2 Q07912 1/20 0.30
CETP P11597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29909725 0.88 ABCG2 (0.33) SCN9ADHODHABCG2EGFRCSF1R
SCHEMBL29909466 0.82 ABL1 (0.33) DHODHABCG2LIPE
SCHEMBL30961041 0.81 DHODH (0.31) SCN9ADHODHABCG2EGFRCSF1R
SCHEMBL29909024 0.77 ABCG2 (0.37) SCN9ADHODHABCG2EGFRCSF1R
SCHEMBL29909148 0.77 DHODH (0.39) SCN9ADHODHABCG2EGFRCSF1R
SCHEMBL30960997 0.76 SCN5A (0.34) DHODHLIPE
SCHEMBL23577146 0.75 SCN9A (0.38) SCN9ADHODHABCG2KDM4CEGFR
SCHEMBL29909368 0.75 CSF1R (0.45) EGFRCSF1RHPGD
SCHEMBL23577126 0.73 TACR1 (0.40) SCN9ADHODHABCG2SMN1; SMN2
SCHEMBL29909622 0.73 TACR1 (0.40) SCN9ADHODHABCG2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK SCN9A 4747/4885DHODH 1705/4885KDM4E 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.